The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
Open accessAbstract
Background Nivolumab plus ipilimumab is approved as first-line regimen for intermediate-risk or poor-risk metastatic renal cell carcinoma, and nivolumab monotherapy as second-line therapy for all risk groups. We aimed to examine the efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab combination as an immunotherapeutic boost after no response to nivolumab monotherapy in patients with intermediate-risk and poor-risk clear-cell metastatic renal cell carcinoma.Methods TITAN-RCC is a multicentre, single-arm, phase 2 trial, done at 28 hospitals and cancer centres across Europe (Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, and the UK). Adults (aged ≥18 years) with histologically confirmed intermediate-risk or poor-risk clear-cell metastatic renal cell carcinoma who were formerly untreated (first-line population) or pretreated with one previous systemic therapy (anti-angiogenic or temsirolimus; second-line population) were eligible. Patients had to have a Karnofsky Performance Status score of at least 70 and measurable disease per Response Evaluation Criteria in Solid Tumours (version 1.1). Patients started with intravenous nivolumab 240 mg once every 2 weeks. On early progressive disease (week 8) or non-response at week 16, patients received two or four doses of intravenous nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) boosts (once every 3 weeks), whereas responders continued with intravenous nivolumab (240 mg, once every 2 weeks), but could receive two to four boost doses of nivolumab plus ipilimumab for subsequent progressive disease. The primary endpoint was confirmed investigator-assessed objective response rate in the full analysis set, which included all patients who received at least one dose of study medication; safety was also assessed in this population. An objective response rate of more than 25% was required to reject the null hypothesis and show improvement, on the basis of results from the pivotal phase 3 CheckMate-025 trial. This study is registered with ClinicalTrials.gov, NCT02917772, and is complete.Findings Between Oct 28, 2016, and Nov 30, 2018, 207 patients were enrolled and all received nivolumab induction (109 patients in the first-line group; 98 patients in the second-line group). 60 (29%) of 207 patients were female and 147 (71%) were male. 147 (71%) of 207 patients had intermediate-risk metastatic renal cell carcinoma and 51 (25%) had poor-risk disease. After median follow-up of 27·6 months (IQR 10·5-34·8), 39 (36%, 90% CI 28-44; p=0·0080) of 109 patients in the first-line group and 31 (32%, 24-40; p=0·083) of 98 patients in the second-line group had a confirmed objective response for nivolumab with and without nivolumab plus ipilimumab. Confirmed response to nivolumab at week 8 or 16 was observed in 31 (28%) of 109 patients in the first-line group and 18 (18%) of 98 patients in the second-line group. The most frequent grade 3-4 treatment-related adverse events (reported in ≥5% of patients) were increased lipase (15 [7%] of 207 patients), colitis (13 [6%]), and diarrhoea (13 [6%]). Three deaths were reported that were deemed to be treatment-related: one due to possible ischaemic stroke, one due to respiratory failure, and one due to pneumonia.Interpretation In treatment-naive patients, nivolumab induction with or without nivolumab plus ipilimumab boosts significantly improved the objective response rate compared with that reported for nivolumab monotherapy in the CheckMate-025 trial. However, overall efficacy seemed inferior when compared with approved upfront nivolumab plus ipilimumab. For second-line treatment, nivolumab plus ipilimumab could be a rescue strategy on progression with approved nivolumab monotherapy.Funding Bristol Myers Squibb.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationHeng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., Mackenzie, M., Wood, L., Donskov, F., Tan, M.-H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70559-4 · Cited by 1,030
Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Self-citationMotzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J. P., Mellado, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00290-9 · Cited by 945
Self-citationHammers, H. J., Plimack, E. R., Infante, J. R., Rini, B. I., McDermott, D. F., Lewis, L. D., Voss, M. H., Sharma, P., Pal, S. K., Razak, A. R. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1985 · Cited by 505
Motzer, R. J., Escudier, B., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Plimack, E. R., Procopio, G., McDermott, D. F., et al. (2020) · Cancer · doi:10.1002/cncr.33033 · Cited by 325
Self-citationMotzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., Barthélémy, P., Plimack, E. R., Porta, C., George, S., et al. (2022) · Cancer · doi:10.1002/cncr.34180 · Cited by 261
Self-citationEscudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.010 · Cited by 256
Self-citation
Research works printed but not linked: 1
- Choueiri, 2022, Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313), Ann Oncol, 33, S808
Cited by
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024: Featured Updates to the NCCN Guidelines
Motzer, R. J., Jonasch, E., Agarwal, N., Alva, A., Bagshaw, H., Baine, M., Beckermann, K., Carlo, M. I., Choueiri, T. K., Costello, B. A., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0008 · Cited by 195
Pharmacogenomics: A Genetic Approach to Drug Development and Therapy
Qahwaji, R. M., Ashankyty, I., Sannan, N., Hazzazi, M. S., Basabrain, A. A., & Mobashir, M. (2024) · Pharmaceuticals · doi:10.3390/ph17070940 · Cited by 117
Liu, Q., Guan, Y., & Li, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02095-8 · Cited by 95
Li, G., Ma, X., Sui, S., Chen, Y., Li, H., Liu, L., Zhang, X., Zhang, L., Hao, Y., Yang, Z., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03200-x · Cited by 58
“To date, Ipilimumab, a CTLA-4 mAb, has proven efficacy in the treatment of certain tumors, such as melanoma [55], non-small cell lung cancer [56], and renal cell carcinoma [57].”
BackgroundCombination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 67
Metadata
- Authors
- Grimm, M.-O., Esteban, E., Barthélémy, P., Schmidinger, M., Busch, J., Valderrama, B. P., Charnley, N., Schmitz, M., Schumacher, U., Leucht, K., Foller, S., Baretton, G., Duran, I., de Velasco, G., Priou, F., Maroto, P., Albiges, L., Barone, C., Castellano, D., Chevreau, C., Gajate Borau, P., Gopalakrishnan, S., Grande, E., Hamid, A., Heinzelbecker, J., Janssen, M., Kopecký, J., Kubala, E., Loidl, W., Lorch, A., Melichar, B., Lainez Milagro, N., Niegisch, G., Ohlmann, C., Sacré, A., Sarwar, N., Schinzari, G., Schrijvers, D., Tartas, S., Wirth, M., Wolter, P., & Zemanova, M.
- Affiliations
- Jena University Hospital (DE)
- Hospital Universitario Central de Asturias (ES)
- Institut de Cancérologie Strasbourg (FR)
- Medical University of Vienna (AT)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital Universitario Virgen del Rocío (ES)
- Royal Preston Hospital (GB)
- German Cancer Research Center (DE)
- Technische Universität Dresden (DE)
- Centre Hospitalier Départemental Vendée (FR)
- Hospital de Sant Pau (ES)
- Université Paris-Saclay (FR)
- Corresponding author
- Grimm, Marc-Oliver
- ORCID
- Grimm, Marc-Oliver
- Esteban, Emilio
- Barthélémy, Philippe
- Schmidinger, Manuela
- Busch, Jonas
- Valderrama, Begoña P
- Charnley, Natalie
- Schmitz, Marc
- Schumacher, Ulrike
- Leucht, Katharina
- Foller, Susan
- Baretton, Gustavo
- Priou, Frank
- Maroto, Pablo
- Albiges, Laurence
- Barone, Carlo
- Castellano, Daniel
- Chevreau, Christine
- Grande, Enrique
- Janssen, Martin
- Kopecký, Jindřich
- Loidl, Wolfgang
- Lorch, Anja
- Melichar, Bohuslav
- Niegisch, Günter
- Ohlmann, Carsten
- Sarwar, Naveed
- Schinzari, Giovanni
- Schrijvers, Dirk
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2023-11
- Volume
- 24
- Issue
- 11
- Pages
- 1252-1265
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4387610648
- Cited by
- 37
- References
- 17
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 13 · 2023: 1
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 181 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Oncology (acceptedVersion)
- PubMed (publishedVersion)
- Funders
- BMS
- AIO-Studien
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- metastatic renal cell carcinoma, clear cell renal cell carcinoma, nivolumab, ipilimumab, immune checkpoint inhibitors, combination immunotherapy, objective response rate, second-line therapy, treatment safety, anti-angiogenic therapy, temsirolimus
- MeSH terms
- Ipilimumab, Nivolumab, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Brain Ischemia, Female, Humans, Immunotherapy, Kidney Neoplasms, Male, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00449-7
- The paper
- Grimm, M.-O., Esteban, E., Barthélémy, P., Schmidinger, M., Busch, J., Valderrama, B. P., Charnley, N., Schmitz, M., Schumacher, U., Leucht, K., Foller, S., Baretton, G., Duran, I., de Velasco, G., Priou, F., Maroto, P., Albiges, L., Barone, C., Castellano, D., . . . Zemanova, M. (2023). Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00449-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.